The development of anti-BRAF targeted therapies represents another step toward a more personalized approach to the management of metastatic CRC. Patients with BRAF V600E-mutant metastatic CRC have a worse prognosis, with a median survival of only 12 months. Although anti-BRAF monotherapy has limited therapeutic efficacy, recent data suggest that combination therapy with a selective BRAF inhibitor (encorafenib) and the anti-EGFR monoclonal antibody cetuximab can improve objective response, progression-free survival, and overall survival in patients with BRAF V600E-mutant metastatic CRC after the failure of first-line treatment and beyond.
Learn more about emerging approaches in precision medicine for metastatic CRC.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Ali Alqahtani. Fast Five Quiz: Precision Medicine and Genetic Testing for Colorectal Cancer - Medscape - Jun 17, 2022.